Results 1 to 10 of about 962,808 (353)

High grade serous ovarian carcinomas originate in the fallopian tube

Nature Communications, 2017
It has previously been proposed that high-grade serous ovarian carcinoma (HGSOC) may originate from the fallopian tube. Here, the authors analyze genetic aberrances in fallopian tube lesions, ovarian cancers, and metastases from HGSOC patients and ...
S Intidhar Labidi-Galy, Eniko Papp, Noushin Niknafs   +2 more
exaly   +3 more sources

Localization and variable expression of Gαi2 in human endometrium and Fallopian tubes [PDF]

, 2007
Background: Heterotrimeric G proteins take part in membrane-mediated cell signalling and have a role in hormonal regulation. This study clarifies the expression and localization of the G protein subunit Gαi2 in the human endometrium and Fallopian tube ...
Aflatoonian, R, Fazeli, A, Laitinen, JT, Lee, KF, Li, TC, Mönkkönen, KS, Tsao, SW, Tuckerman, EM, Yeung, WSB   +8 more
core   +3 more sources

Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma [PDF]

Nature Communications, 2019
The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial, with fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) both considered candidates.
Shuang Zhang, Igor Dolgalev, Tao Zhang, Hao Ran, Douglas A. Levine, Benjamin G. Neel   +5 more
openalex   +2 more sources

Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution [PDF]

Nature Communications, 2016
The exact timing and contribution of epigenetic reprogramming to carcinogenesis are unclear. Women harbouring BRCA1/2 mutations demonstrate a 30–40-fold increased risk of high-grade serous extra-uterine Müllerian cancers (HGSEMC), otherwise referred to ...
Arora, R, Bartlett, TE, Beck, S, Breeze, CE, Chindera, K, Cooke, WR, Dubeau, L, Jones, A, Karegodar, ST, McDermott, J, Menon, U, Reisel, D, Widschwendter, M   +12 more
core   +3 more sources

Primary Fallopian Tube Carcinoma [PDF]

, 2011
Primary Fallopian Tube Carcinoma (PFTC) is rare and accounts for about 0.3% of all gynecologic cancers. Less than 1500 cases have been reported in the literature.
Bafna, UD, K, Balaiah, S, Gnana Prakash, Shetty, Prasad K   +3 more
core   +3 more sources

Primary Transitional Cell Carcinoma of the Fallopian Tube [PDF]

Online Journal of Health & Allied Sciences, 2012
Primary carcinoma of the fallopian tube is a rare entity that accounts for 0.2-0.5% of all gynecologic malignancies, and most are discovered during or after surgery.
Kavita Mardi, Vijay Kaushal
doaj   +2 more sources

A Rare Case Of Fallopian Tube Cancer [PDF]

Online Journal of Health & Allied Sciences, 2008
Fallopian tube carcinoma is a very rare malignancy and we report a case of stage IIC primary fallopian tube cancer.
Joydeb Roychowdhury, Madhavi Panpalia
doaj   +2 more sources

Identification of novel differentiation trajectories and gene network associations with ectopic pregnancy in fallopian tube epithelium. [PDF]

Hum Reprod
Wright LI, Wangsaputra I, Garner T, Sharps MC, Sturmey R, Ruane PT, Stevens A.   +6 more
europepmc   +2 more sources

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2021
In 2014, FIGO’s Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC).
J. Berek, M. Renz, S. Kehoe, L. Kumar, M. Friedlander   +4 more
semanticscholar   +1 more source

Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

International Journal of Gynecological Pathology, 2022
The move toward consistent and comprehensive surgical pathology reports for cancer resection specimens has been a key development in supporting evidence-based patient management and consistent cancer staging.
C. Gilks, Christina I. Selinger, Ben Davidson, M. Köbel, J. Ledermann, Diana Lim, Anais Malpica, Y. Mikami, Naveena Singh, Radhika Srinivasan, R. Vang, Sigurd F Lax, W. McCluggage   +12 more
semanticscholar   +1 more source